Header Logo

Connection

Andrew Ambrosy to Heart Failure

Back to Details
This is a "connection" page, showing publications Andrew Ambrosy has written about Heart Failure.
Andrew Ambrosy
Connection Strength
23.855
Heart Failure
  1. Fluid Restriction Recommendations in Heart Failure: Dry as a Bone or Quench Your Thirst? J Card Fail. 2022 10; 28(10):1531-1533.
    View in: PubMed
    Score: 0.568
  2. Analysis of Worsening Heart Failure Events in an Integrated Health Care System. J Am Coll Cardiol. 2022 Jul 12; 80(2):111-122.
    View in: PubMed
    Score: 0.564
  3. Food security, diet quality, nutritional knowledge, and attitudes towards research in adults with heart failure during the COVID-19 pandemic. Clin Cardiol. 2022 Feb; 45(2):180-188.
    View in: PubMed
    Score: 0.547
  4. A Natural Language Processing-Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. JAMA Netw Open. 2021 11 01; 4(11):e2135152.
    View in: PubMed
    Score: 0.538
  5. Improving adherence to guideline-directed medical therapies and outcomes in the developing world: A call to end global inequities in heart failure. Int J Cardiol. 2021 04 15; 329:74-76.
    View in: PubMed
    Score: 0.505
  6. Hospitalizations for heart failure and mortality risk during the evolving coronavirus disease 2019 pandemic - the wave may break but a dangerous undertow persists. Eur J Heart Fail. 2020 12; 22(12):2225-2227.
    View in: PubMed
    Score: 0.503
  7. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
    View in: PubMed
    Score: 0.496
  8. Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns. Eur J Heart Fail. 2020 10; 22(10):1752-1754.
    View in: PubMed
    Score: 0.493
  9. Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest. Eur J Heart Fail. 2020 09; 22(9):1734-1736.
    View in: PubMed
    Score: 0.491
  10. A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. Int J Cardiol. 2020 06 15; 309:95-99.
    View in: PubMed
    Score: 0.480
  11. Hyperglycemia and outcomes in acute heart failure - A bittersweet relationship. Int J Cardiol. 2020 02 01; 300:196-197.
    View in: PubMed
    Score: 0.469
  12. Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? Eur J Heart Fail. 2019 11; 21(11):1398-1401.
    View in: PubMed
    Score: 0.459
  13. A Balancing Act: Preserving Renal Function and the Need for Decongestion. J Card Fail. 2019 08; 25(8):643-644.
    View in: PubMed
    Score: 0.457
  14. In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. Eur J Heart Fail. 2019 08; 21(8):1008-1011.
    View in: PubMed
    Score: 0.456
  15. Applying data science approaches to identify frequent flyers in heart failure: rise of the machines. Eur J Heart Fail. 2019 03; 21(3):319-321.
    View in: PubMed
    Score: 0.445
  16. Combination drug therapy in heart failure: greater than the sum of its parts. Eur J Heart Fail. 2018 09; 20(9):1323-1325.
    View in: PubMed
    Score: 0.426
  17. Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Am Heart J. 2018 05; 199:176-177.
    View in: PubMed
    Score: 0.416
  18. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. Am Heart J. 2018 05; 199:97-104.
    View in: PubMed
    Score: 0.415
  19. Sudden cardiac death following admission for acute heart failure: adding insult to injury. Eur J Heart Fail. 2018 03; 20(3):533-535.
    View in: PubMed
    Score: 0.412
  20. Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement. Eur J Heart Fail. 2017 11; 19(11):1424-1426.
    View in: PubMed
    Score: 0.401
  21. Clinical profiles in acute heart failure: one size fits all or not at all? Eur J Heart Fail. 2017 10; 19(10):1255-1257.
    View in: PubMed
    Score: 0.401
  22. Clinical trials in acute heart failure: beginning of the end or end of the beginning? Eur J Heart Fail. 2017 11; 19(11):1358-1360.
    View in: PubMed
    Score: 0.398
  23. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). Am J Cardiol. 2017 07 01; 120(1):98-105.
    View in: PubMed
    Score: 0.392
  24. Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. Am Heart J. 2017 Apr; 186:130-138.
    View in: PubMed
    Score: 0.386
  25. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. JACC Heart Fail. 2017 01; 5(1):1-13.
    View in: PubMed
    Score: 0.385
  26. Targeting digoxin dosing to serum concentration: is the bullseye too small? Eur J Heart Fail. 2016 08; 18(8):1082-4.
    View in: PubMed
    Score: 0.374
  27. Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. JACC Heart Fail. 2016 05; 4(5):365-7.
    View in: PubMed
    Score: 0.367
  28. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circ Heart Fail. 2016 05; 9(5).
    View in: PubMed
    Score: 0.367
  29. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2016 Mar; 18(3):306-13.
    View in: PubMed
    Score: 0.353
  30. Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study. Heart Fail Clin. 2015 Oct; 11(4):581-9.
    View in: PubMed
    Score: 0.349
  31. Effect of minor liver function test abnormalities and values within the normal range on survival in heart failure. Am J Cardiol. 2015 Apr 01; 115(7):938-41.
    View in: PubMed
    Score: 0.336
  32. Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. Curr Heart Fail Rep. 2014 Dec; 11(4):416-27.
    View in: PubMed
    Score: 0.333
  33. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014 May 13; 63(18):1823-32.
    View in: PubMed
    Score: 0.316
  34. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 01; 63(12):1123-1133.
    View in: PubMed
    Score: 0.314
  35. The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry. Eur Heart J Acute Cardiovasc Care. 2013 Jun; 2(2):99-108.
    View in: PubMed
    Score: 0.300
  36. Not time to RELAX in acute heart failure. Lancet. 2013 May 25; 381(9880):1813.
    View in: PubMed
    Score: 0.300
  37. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013 Mar; 34(11):835-43.
    View in: PubMed
    Score: 0.292
  38. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013 Feb; 165(2):216-25.
    View in: PubMed
    Score: 0.291
  39. B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF. J Cardiovasc Med (Hagerstown). 2012 Jun; 13(6):360-7.
    View in: PubMed
    Score: 0.280
  40. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail. 2012 Mar; 14(3):302-11.
    View in: PubMed
    Score: 0.275
  41. Acute heart failure syndromes: assessment and reconstructing the heart. J Cardiovasc Med (Hagerstown). 2011 Apr; 12(4):258-63.
    View in: PubMed
    Score: 0.258
  42. Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother. 2011 Apr; 12(6):961-76.
    View in: PubMed
    Score: 0.257
  43. Heart failure in 2010: one step forward, two steps back. Nat Rev Cardiol. 2011 Feb; 8(2):72-3.
    View in: PubMed
    Score: 0.255
  44. Predictors of Incident Heart?Failure Diagnosis Setting: Insights From the Veterans Affairs Healthcare System. JACC Heart Fail. 2023 03; 11(3):347-358.
    View in: PubMed
    Score: 0.147
  45. Predicting short-term outcomes after transcatheter aortic valve replacement for aortic stenosis. Am Heart J. 2023 02; 256:60-72.
    View in: PubMed
    Score: 0.144
  46. Variation in Heart Failure Risk by HIV Severity and Sex in People With HIV Infection. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):175-181.
    View in: PubMed
    Score: 0.143
  47. Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas. ESC Heart Fail. 2022 12; 9(6):3713-3736.
    View in: PubMed
    Score: 0.143
  48. Effect of Medically Tailored Meals on Clinical Outcomes in Recently Hospitalized High-Risk Adults. Med Care. 2022 10 01; 60(10):750-758.
    View in: PubMed
    Score: 0.142
  49. Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician. Curr Atheroscler Rep. 2022 Jul; 24(7):563-570.
    View in: PubMed
    Score: 0.139
  50. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. Am Heart J. 2022 May; 247:76-89.
    View in: PubMed
    Score: 0.137
  51. Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. ESC Heart Fail. 2022 04; 9(2):947-952.
    View in: PubMed
    Score: 0.137
  52. Temporal trends in the outcomes of acute heart failure: between consolatory evidences and real progress. Eur J Heart Fail. 2021 03; 23(3):432-435.
    View in: PubMed
    Score: 0.128
  53. Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure With Preserved Ejection Fraction-Reply. Mayo Clin Proc. 2021 02; 96(2):503-506.
    View in: PubMed
    Score: 0.128
  54. Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. ESC Heart Fail. 2021 02; 8(1):662-669.
    View in: PubMed
    Score: 0.126
  55. The Degree of the Predischarge Pulmonary Congestion in Patients Hospitalized for Worsening Heart Failure Predicts Readmission and Mortality. Cardiology. 2021; 146(1):49-59.
    View in: PubMed
    Score: 0.125
  56. Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. JACC Cardiovasc Interv. 2020 10 26; 13(20):2331-2341.
    View in: PubMed
    Score: 0.125
  57. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
    View in: PubMed
    Score: 0.124
  58. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 10; 8(10):789-799.
    View in: PubMed
    Score: 0.122
  59. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiol. 2020 06 01; 5(6):643-651.
    View in: PubMed
    Score: 0.122
  60. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. Circ Heart Fail. 2020 05; 13(5):e006758.
    View in: PubMed
    Score: 0.121
  61. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. Eur J Heart Fail. 2020 06; 22(6):1022-1031.
    View in: PubMed
    Score: 0.120
  62. One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. Eur J Heart Fail. 2020 05; 22(5):859-867.
    View in: PubMed
    Score: 0.120
  63. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
    View in: PubMed
    Score: 0.119
  64. A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). J Cardiovasc Transl Res. 2020 08; 13(4):540-548.
    View in: PubMed
    Score: 0.119
  65. Association between systolic ejection time and outcomes in heart failure by ejection fraction. Eur J Heart Fail. 2020 07; 22(7):1174-1182.
    View in: PubMed
    Score: 0.118
  66. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure? Am Heart J. 2020 02; 220:97-107.
    View in: PubMed
    Score: 0.117
  67. Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. Eur J Heart Fail. 2019 11; 21(11):1472-1476.
    View in: PubMed
    Score: 0.116
  68. Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. Can J Cardiol. 2019 09; 35(9):1097-1105.
    View in: PubMed
    Score: 0.111
  69. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. Eur J Heart Fail. 2018 12; 20(12):1760-1763.
    View in: PubMed
    Score: 0.109
  70. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
    View in: PubMed
    Score: 0.109
  71. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Fail. 2018 12; 5(6):1035-1043.
    View in: PubMed
    Score: 0.108
  72. Expanded algorithm for managing patients with acute decompensated heart failure. Heart Fail Rev. 2018 07; 23(4):597-607.
    View in: PubMed
    Score: 0.107
  73. Improving Postdischarge Outcomes in Acute Heart Failure. Am J Ther. 2018 Jul/Aug; 25(4):e475-e486.
    View in: PubMed
    Score: 0.107
  74. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 04; 198:145-151.
    View in: PubMed
    Score: 0.103
  75. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2018 02; 20(2):304-314.
    View in: PubMed
    Score: 0.102
  76. Lessons learned in acute heart failure. Eur J Heart Fail. 2018 04; 20(4):630-641.
    View in: PubMed
    Score: 0.102
  77. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018 02; 20(2):281-291.
    View in: PubMed
    Score: 0.102
  78. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. J Am Coll Cardiol. 2017 Jun 27; 69(25):3029-3039.
    View in: PubMed
    Score: 0.099
  79. Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure. JACC Heart Fail. 2017 04; 5(4):311-312.
    View in: PubMed
    Score: 0.098
  80. Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. Curr Heart Fail Rep. 2017 02; 14(1):30-39.
    View in: PubMed
    Score: 0.097
  81. Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur J Heart Fail. 2017 04; 19(4):552-562.
    View in: PubMed
    Score: 0.095
  82. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Circ Heart Fail. 2016 09; 9(9).
    View in: PubMed
    Score: 0.094
  83. Natriuretic peptide-guided management in heart failure. J Cardiovasc Med (Hagerstown). 2016 Aug; 17(8):556-68.
    View in: PubMed
    Score: 0.093
  84. Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. JACC Heart Fail. 2016 06; 4(6):419-27.
    View in: PubMed
    Score: 0.092
  85. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. JACC Heart Fail. 2016 07; 4(7):580-588.
    View in: PubMed
    Score: 0.091
  86. Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry. J Cardiovasc Med (Hagerstown). 2016 Feb; 17(2):92-104.
    View in: PubMed
    Score: 0.090
  87. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. Am J Cardiol. 2016 Apr 01; 117(7):1144-50.
    View in: PubMed
    Score: 0.090
  88. Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. Heart Fail Clin. 2015 Oct; 11(4):591-601.
    View in: PubMed
    Score: 0.087
  89. Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. Eur J Heart Fail. 2015 Oct; 17(10):1022-31.
    View in: PubMed
    Score: 0.086
  90. Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry. J Cardiovasc Med (Hagerstown). 2015 May; 16(5):331-40.
    View in: PubMed
    Score: 0.086
  91. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015 May; 17(5):527-33.
    View in: PubMed
    Score: 0.085
  92. Lipids, statins, and clinical outcomes in heart failure: rethinking the data. Heart Fail Rev. 2014 Nov; 19(6):695-8.
    View in: PubMed
    Score: 0.083
  93. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014 Dec 01; 114(11):1713-21.
    View in: PubMed
    Score: 0.082
  94. Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J. 2014 Aug; 168(2):142-9.
    View in: PubMed
    Score: 0.080
  95. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circ Heart Fail. 2014 May; 7(3):401-8.
    View in: PubMed
    Score: 0.080
  96. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). Am J Cardiol. 2013 Dec 01; 112(11):1763-9.
    View in: PubMed
    Score: 0.077
  97. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec; 15(12):1401-11.
    View in: PubMed
    Score: 0.076
  98. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev. 2013 Mar; 18(2):107-22.
    View in: PubMed
    Score: 0.074
  99. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013 Feb; 10(2):85-97.
    View in: PubMed
    Score: 0.073
  100. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013 Jan; 6(1):47-52.
    View in: PubMed
    Score: 0.073
  101. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013 Feb 05; 61(5):571-9.
    View in: PubMed
    Score: 0.073
  102. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol. 2013 Feb 15; 111(4):574-81.
    View in: PubMed
    Score: 0.072
  103. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J. 2012 Dec; 164(6):884-92.e2.
    View in: PubMed
    Score: 0.072
  104. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2012 Nov; 5(6):750-8.
    View in: PubMed
    Score: 0.072
  105. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur J Heart Fail. 2013 Jan; 15(1):61-8.
    View in: PubMed
    Score: 0.071
  106. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012 May; 17(3):485-509.
    View in: PubMed
    Score: 0.070
  107. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. Discov Med. 2011 Aug; 12(63):141-51.
    View in: PubMed
    Score: 0.066
  108. The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. Am Heart J. 2011 Jul; 162(1):142-53.e1.
    View in: PubMed
    Score: 0.065
  109. Association Between Aging of the US Population and Heart Disease Mortality From 2011 to 2017. JAMA Cardiol. 2019 12 01; 4(12):1280-1286.
    View in: PubMed
    Score: 0.029
  110. Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. Curr Cardiol Rep. 2017 08; 19(8):71.
    View in: PubMed
    Score: 0.025

© 2024 Kaiser Permanente